In conclusion, our study elucidates the regulatory role of NCBP1 in tumorigenesis and development, and it is perhaps a potential novel diagnostic and prognostic biomarker in DLBCL and can be used as a therapeutic target. This evidence concerns the gene NCBP1 and diffuse large B-cell lymphoma.